Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Once-monthly dosing: an effective step forward.

D M Reid1

  • 1Department of Medicine and Therapeutics, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK. d.m.reid@abdn.ac.uk

Bone
|March 15, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Introducing mobile fracture prevention services with DXA in Northern Scotland: a comparative study of three rural communities.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2020
Same author

Characterization of Biofilm Formation by Xylella fastidiosa In Vitro.

Plant disease·2019
Same author

Significant morphological change in osteoarthritic hips identified over 6-12 months using statistical shape modelling.

Osteoarthritis and cartilage·2018
Same author

UK clinical guideline for the prevention and treatment of osteoporosis.

Archives of osteoporosis·2017
Same author

CD4(+) T-cell survival in the GI tract requires dectin-1 during fungal infection.

Mucosal immunology·2015
Same author

FRAX-based assessment and intervention thresholds--an exploration of thresholds in women aged 50 years and older in the UK.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2015
Same journal

Bone density-based maturation of the midpalatal suture in children aged 8-15 years.

Bone·2026
Same journal

Disrupted phosphate metabolism and SIBLING/ASARM peptide accumulation underlie impaired bone mineralization in klotho-deficient (kl/kl) mice.

Bone·2026
Same journal

Linking genetic variants to bone microstructure: Histological signatures of osteogenesis imperfecta subtypes.

Bone·2026
Same journal

The impact of alcohol consumption on bone mineral density: Insights from cross-sectional and Mendelian randomization studies.

Bone·2026
Same journal

Systemic and local predictors of medication-related osteonecrosis of the jaw in patients receiving antiresorptive therapy: The Shizuoka Kokuho Database study.

Bone·2026
Same journal

Long-term exposure to ambient air pollution and risk of non-traumatic osteonecrosis of the femoral head: A nationwide cohort study.

Bone·2026
See all related articles

Monthly ibandronate significantly increased bone mineral density and reduced bone turnover markers in postmenopausal osteoporosis. This convenient dosing regimen offers improved adherence and comparable safety to daily bisphosphonates.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Bone Metabolism

Background:

  • Suboptimal therapeutic adherence with bisphosphonates is a challenge in postmenopausal osteoporosis.
  • Less-frequent dosing regimens are needed for improved patient convenience and adherence.

Purpose of the Study:

  • To evaluate the efficacy and safety of a once-monthly oral ibandronate dosing schedule for postmenopausal osteoporosis.
  • To compare monthly ibandronate regimens with daily oral ibandronate.

Main Methods:

  • The MOBILE study was a large, randomized, double-blind, non-inferiority trial involving 1609 women with postmenopausal osteoporosis.
  • Participants received monthly oral ibandronate (50+50 mg, 100 mg, or 150 mg) or daily oral ibandronate (2.5 mg) for 2 years.
  • Bone mineral density (BMD) and biochemical markers of bone turnover (serum and urinary CTX) were assessed.

Related Experiment Videos

Main Results:

  • All once-monthly ibandronate regimens demonstrated non-inferiority to daily dosing in increasing lumbar spine BMD (5.3-6.6%).
  • The 150 mg monthly regimen was superior to daily ibandronate in increasing lumbar spine BMD (P < or = 0.002).
  • Significant reductions in CTX levels were observed with all regimens, maintained over 2 years, with a comparable safety profile.

Conclusions:

  • Once-monthly oral ibandronate is an effective and well-tolerated treatment for postmenopausal osteoporosis.
  • The 150 mg monthly regimen showed superior efficacy in increasing BMD compared to daily dosing.
  • Improved patient adherence is anticipated due to the convenience of monthly dosing, potentially enhancing treatment outcomes.